Overview

A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

Status:
Completed

Trial end date:
2016-03-18

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy of GWP42003-P as adjunctive treatment in reducing the number of drop seizures when compared with placebo, in participants with Lennox-Gastaut Syndrome (LGS).

Phase:

Phase 3

Details

Lead Sponsor:

GW Research Ltd

Treatments:

Cannabidiol
Pharmaceutical Solutions